Fujimori A - Search Results

1

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.

Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Tanizawa A, et al. Among authors: fujimori y, fujimori a. J Natl Cancer Inst. 1994 Jun 1;86(11):836-42. doi: 10.1093/jnci/86.11.836. J Natl Cancer Inst. 1994. PMID: 8182764

2

Eukaryotic DNA topoisomerases I.

Gupta M, Fujimori A, Pommier Y. Gupta M, et al. Among authors: fujimori a. Biochim Biophys Acta. 1995 May 17;1262(1):1-14. doi: 10.1016/0167-4781(95)00029-g. Biochim Biophys Acta. 1995. PMID: 7772596 Review. No abstract available.

3

Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.

Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y. Fujimori A, et al. Cancer Res. 1995 Mar 15;55(6):1339-46. Cancer Res. 1995. PMID: 7882333

4

Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells.

Fujimori A, Hoki Y, Popescu NC, Pommier Y. Fujimori A, et al. Oncol Res. 1996;8(7-8):295-301. Oncol Res. 1996. PMID: 8938793

Camptothecin resistance of the human leukemia CEM/C2 cells is associated with a topoisomerase I (top1) mutation: Asn722Ser (Fujimori, A. et al. ...These results indicate that gene-specific DNA methylation can play a role in downregulating top1 gene(s) …

Camptothecin resistance of the human leukemia CEM/C2 cells is associated with a topoisomerase I (top1) mutation: Asn722Ser (Fujimo …

5

Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.

Fujimori A, Gupta M, Hoki Y, Pommier Y. Fujimori A, et al. Mol Pharmacol. 1996 Dec;50(6):1472-8. Mol Pharmacol. 1996. PMID: 8967967

6

Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines.

Hoki Y, Fujimori A, Pommier Y. Hoki Y, et al. Among authors: fujimori a. Cancer Chemother Pharmacol. 1997;40(5):433-8. doi: 10.1007/s002800050682. Cancer Chemother Pharmacol. 1997. PMID: 9272121

7

In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.

Pondarré C, Strumberg D, Fujimori A, Torres-León R, Pommier Y. Pondarré C, et al. Among authors: fujimori a. Nucleic Acids Res. 1997 Oct 15;25(20):4111-6. doi: 10.1093/nar/25.20.4111. Nucleic Acids Res. 1997. PMID: 9321666 Free PMC article.

8

Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.

Kapoor R, Slade DL, Fujimori A, Pommier Y, Harker WG. Kapoor R, et al. Among authors: fujimori a. Oncol Res. 1995;7(2):83-95. Oncol Res. 1995. PMID: 7579731

9

Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors.

Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G, Kohn KW. Pommier Y, et al. Among authors: fujimori a. Cancer Invest. 1994;12(5):530-42. doi: 10.3109/07357909409021413. Cancer Invest. 1994. PMID: 7922710 Review. No abstract available.

10

Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions.

Leteurtre F, Fujimori A, Tanizawa A, Chhabra A, Mazumder A, Kohlhagen G, Nakano H, Pommier Y. Leteurtre F, et al. Among authors: fujimori a. J Biol Chem. 1994 Nov 18;269(46):28702-7. J Biol Chem. 1994. PMID: 7961822 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

454 results

Search Page